PRESS RELEASE
December 27, 2010

Gambro finalizes the sale of its global PD business to Fresenius Medical Care

Gambro today announced it has finalized* the sale of its global peritoneal dialysis (PD) business to Fresenius Medical Care. The ownership of Gambro's solutions manufacturing plant in Canosa, Italy will coincide with the transfer of the manufacturing license expected to occur in early 2011.

"The sale of our global PD-business allows us to prioritize our investments and increase our focus in the areas where we have a competitive position and can generate most value for our customers and our company," says Thomas Glanzmann, Gambro's President and CEO.

The transaction is part of Gambro's strategy to focus on its core businesses. During 2010, Gambro has actualized this strategy through the acquisition of CHF Solutions Ltd, the licensing of its US water business to MarCor (a division of Cantel Medical Corporation) and the decision to invest in increased dialyzer capacity at its dialyzer plant in Hechingen, Germany.

For further information please contact:
Maria Lundbäck, Director External Communications Gambro, tel. +46 705 13 6534

*** Gambro's Serbian business is expected to be transferred following the receipt of certain required regulatory approvals early 2011.**

Every day, Gambro's products save, sustain and improve the lives of patients worldwide through innovative products and therapies for Kidney and Liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for Chronic and Acute patients. Founded in 1964, Gambro today has 8 000 employees, production facilities in 9 countries, and sales in more than 100 countries.
.

Gambro
Regeringsgatan 29
Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8 613 65 00
www.gambro.com